[Case Report: Histological Transformation to Atypical Carcinoid in RET Fusion-positive NSCLC Following Immune Therapy Resistance] [0.03%]
【病例报告】免疫治疗耐药后RET融合阳性肺癌发生非典型类癌的组织学转化
Yu Zhang,Hui Zhang,Wei Zhong et al.
Yu Zhang et al.
Immune checkpoint inhibitors (ICIs) have become the cornerstone of treatment for driver gene-negative advanced non-small cell lung cancer (NSCLC). However, resistance is inevitable, and the underlying mechanisms remain incompletely understo...
Jie Yang,Fanming Kong
Jie Yang
Malignant pleural mesothelioma (MPM) is a highly aggressive malignancy originating from mesothelial cells of the pleura, primarily associated with asbestos exposure, and is often characterized by poor prognosis. Due to the lack of specific ...
Jialong Chen,Lei Zhou,Lingling Qin et al.
Jialong Chen et al.
In recent years, the widespread application of chest computed tomography (CT) screening has led to a significant increase in the detection rate of pulmonary nodules. As a critical diagnostic tool for early-stage lung cancer, video-assisted ...
Fan Xu,Bin Luo,Jianhui Tian et al.
Fan Xu et al.
Lung cancer is the malignant tumor with the highest morbidity and mortality. The tumor-node-metastasis (TNM) staging has gradually shown its limitations in the accurate prediction of lung cancer, so it is urgent to construct a new clinical ...
Zhibo Feng,Xiyang Tang,Yao Lv et al.
Zhibo Feng et al.
Immune checkpoint blockade therapy has demonstrated remarkable efficacy in treating various malignancies; however, its clinical application remains challenged by low response rates and immune-related adverse events. Immunoglobulin superfami...
[Research and Therapeutic Advances of 26S Proteasome Subunit in Non-small Cell Lung Cancer] [0.03%]
【非小细胞肺癌中26S蛋白酶体亚基研究及治疗进展】
Chenrui Mou,Shaotong Zou,Chao Ren et al.
Chenrui Mou et al.
Lung cancer is one of the most common cancers worldwide and is the leading cause of cancer deaths. Lung adenocarcinoma is the most common type of lung cancer. Due to the lack of effective biomarkers and therapeutic targets in the proliferat...
[Advances in Radiotherapy for Extensive-stage Small Cell Lung Cancer in the Era of Immunotherapy] [0.03%]
免疫治疗时代的广泛期小细胞肺癌放疗进展
Tingting Chen,Yanling Yang,Haonan Han et al.
Tingting Chen et al.
Small cell lung cancer (SCLC) is the thoracic malignant tumor and accounts for about 15% of lung malignancies and transfer often occurs by the time of diagnosis. Extensive stage-small cell lung cancer (ES-SCLC) accounts for about 2/3 of all...
Xinyue Yang,Zhiwei Tang,Li Ma et al.
Xinyue Yang et al.
In epidemiological statistics, the incidence rate and mortality rate of malignant lung tumors rank among the top. Non-small cell lung cancer (NSCLC) constitutes an important part of lung cancer and has become a key focus of clinical researc...
[Research Status and Progress of Third-generation EGFR-TKIs in Elderly Patients with Non-small Cell Lung Cancer] [0.03%]
[三代EGFR-TKIs老年非小细胞肺癌的研究进展]
Xue Chen,Yijia Sun,Lihong Zhang et al.
Xue Chen et al.
For patients with advanced non-small cell lung cancer (NSCLC) harboring sensitive epidermal growth factor receptor (EGFR) mutations, guidelines prioritize the use of third-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs), which offer ...
[Predictive Value of miRNAs Markers for Advanced Lung Squamous Cell Carcinoma] [0.03%]
[miRNA标志物预测晚期肺鳞癌的价值]
Anna Wang,Jingjing Cong,Yingjia Wang et al.
Anna Wang et al.
Background: Lung cancer is one of the leading causes of cancer-related mortality worldwide, with above 80% of cases be non-small cell lung cancer (NSCLC), among which lung squamous cell carcinoma (LUSC) occupies a signifi...